跳至主要内容
临床试验/NCT01761981
NCT01761981招募中不适用

Institutional Registry of Haemorrhagic Hereditary Telangiectasia

Hospital Italiano de Buenos Aires1 个研究点 分布在 1 个国家目标入组 590 人开始时间: 2010年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
590
试验地点
1
主要终点
morbidity

研究概览

简要总结

The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.

This study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia in the population of HIBA in the Central Hospital, as well as the characteristics of clinical presentation and evolution.

详细描述

Haemorrhagic Hereditary Telangiectasia is a uncommon autosomic hereditary disorder caracterizad for recurrent epistaxis,cutaneomucous telangiectasias and arteriovenous malformations in diferent organs; brain, lung, liver and gastrointestinal are more often afected . Afect one in 5000-8000 individual in worldwide. HHT may produce important morbidity like brain absces, stroke, hemoptisis and cronic ferropenic anemia.

Molecular mechanism of this disorder are complex and still no fully dilucidated. The genes mutated in HHT encode endothelial cell-expressed proteins that mediate signalling by the transforming growth factor (TGF)b superfamily. Endoglin (HHT type I) and ACVRL-1 (HHT type 2) mutations are responsible in more than 80% of the individuals. Mutation of SMAD 4 protein (MADH4)cause HHT in association with juvenile polyposis. HHT may associated with primary pulmonary hypertension en more rare cases.

There are not HHT registry in Argentina and Latinamerican population. This registry may gader valious information in order to generate a better diagnosis and treatment of our population and others.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with HHT defined.
  • Followed in Unidad HHT of Hospital Italiano de Buenos Aires.

排除标准

  • 1. Denied to participated in the registry or inform consent process.

结局指标

主要结局

morbidity

时间窗: 1 year

Control visit every three month

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

MARCELO MARTIN SERRA

Marcelo Martin Serra

Hospital Italiano de Buenos Aires

研究点 (1)

Loading locations...

相似试验